Diaxonhit Stock Euronext Paris
Stocks
FR0004054427
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 253M 288M 239M 218M 407M 27.6B 410M 2.86B 1.11B 14.1B 1.08B 1.06B 45.32B | P/E 2026 * |
22.2x | P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 221M 252M 208M 190M 356M 24.11B 358M 2.49B 966M 12.32B 944M 924M 39.58B | EV / Sales 2026 * |
1.25x | EV / Sales 2027 * | - |
| Free-Float |
98.24% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -1.83% |
| Manager | Title | Age | Since |
|---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | 58 | 2023-06-12 |
Olivier Bosc
DFI | Director of Finance/CFO | - | 2023-10-09 |
Maarten Penning
CTO | Chief Tech/Sci/R&D Officer | - | 2023-06-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 2018-12-31 | |
Michel Picot
BRD | Director/Board Member | 73 | 2019-06-26 |
| Director/Board Member | 69 | 2017-06-14 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.83% | -.--% | - | - | 288M | |
| -0.14% | +4.33% | +9.00% | +31.64% | 47.97B | |
| -1.69% | +1.48% | +50.57% | +34.53% | 44.5B | |
| +2.56% | +7.34% | +366.69% | +608.26% | 43.93B | |
| +0.24% | +2.85% | +10.67% | +94.47% | 41.03B | |
| -0.62% | -1.11% | +4.65% | +48.91% | 29.85B | |
| -0.28% | +1.07% | +24.58% | +155.58% | 17.27B | |
| +3.37% | +9.21% | +8.32% | - | 15.34B | |
| -0.46% | +1.20% | +26.90% | +42.21% | 15.3B | |
| -2.21% | -4.70% | - | - | 14.82B | |
| Average | -0.11% | +2.35% | +62.67% | +145.08% | 30B | |
| Weighted average by Cap. | +0.11% | +2.86% | +79.67% | +160.28% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 176M 200M 166M 151M 283M 19.21B 285M 1.99B 770M 9.82B 753M 736M 31.55B | - |
| Net income | 11.6M 13.22M 10.96M 9.98M 18.69M 1.27B 18.82M 131M 50.78M 647M 49.63M 48.56M 2.08B | - |
| Net Debt | -32M -36.47M -30.22M -27.54M -51.56M -3.5B -51.93M -362M -140M -1.79B -137M -134M -5.74B | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
